Directors From 206 Care Centers Sign On To A Letter Citing Clinical Consequences Of Vertex Decision

Recently, 206 care center program directors signed a letter to Vertex explaining that their decision to implement changes to their copay assistance program would negatively impact the CF community, with potential for clinical implications. The Foundation continues urging Vertex to reverse their decision before it goes into effect January 1.

Newly Expanded CF Foundation Lab Will Enable More Research Into Genetic Therapies

We’re excited to announce that we expanded the CF Foundation’s lab footprint. This expansion creates room for startup companies and industry scientists to work and learn alongside lab staff. By sharing our expertise, we will help speed up the development of new treatments.

Read about the expansion »

A group of men and women wearing white lab coats stand on steps in front of a building with their hands raised in the air.

The Latest in CF Research

We have invested up to an additional $4.85 million in Aridis Pharmaceuticals to complete a Phase 2a clinical trial for a non-traditional anti-infective drug that could help fight drug-resistant infections in people with cystic fibrosis.

Learn more »

NACFC Highlights Webinar Now Available on YouTube

In case you missed it, the recording from our NACFC highlights webinar with CF research experts is now available to watch on YouTube. Among other research and care news, you will learn about the results of the Simplify study, in addition to the latest genetic therapies under development.

Watch the recording »

WE WILL NOT REST UNTIL WE FIND A CURE

DONATE

www.cff.org

4550 Montgomery Avenue, Suite 1100N | Bethesda, MD 20814 US

Got this as a forward? Sign up to receive our future emails.

Opt out of this mailing list | Opt out of all CFF emails

This email was sent to [email protected].
To continue receiving our emails, add us to your address book.